Evidence map›Paper›PMID 38504051›Full record

SynthesisEndocrine2024

Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.

Sataksi Chatterjee, Manish Mair, Ashok R Shaha, Vinidh Paleri, Shikhar Sawhney, Aananya Mishra, Swayambhu Bhandarkar, Anil Keith D'Cruz

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Multilayered Insights into Poorly Differentiated,Diagnostics (Basel, Switzerland) · 2025
    Article
  7. Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024
    Review
  8. Redo Thyroidectomy: Updated Insights.Journal of clinical medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Sataksi ChatterjeeApollo Hospitals Group, Department of Oncology, Navi Mumbai, Maharashtra, India.
Manish MairDepartment of Otorhinolaryngology, University Hospitals of Leicester, Leicester, UK.
Ashok R ShahaHead and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Vinidh PaleriRoyal Marsden Hospital, London, UK.
Shikhar SawhneyAmrita Institute of Medical Sciences and Research Center, Faridabad, India.
Aananya MishraApollo Hospitals Group, Department of Oncology, Navi Mumbai, Maharashtra, India.
Swayambhu BhandarkarApollo Hospitals Group, Department of Oncology, Navi Mumbai, Maharashtra, India.
Anil Keith D'CruzApollo Hospitals Group, Department of Oncology, Navi Mumbai, Maharashtra, India. docdcruz@gmail.com.
Apollo Hospitals · INAmrita Institute of Medical Sciences and Research Centre · INMemorial Sloan Kettering Cancer Center · USRoyal Marsden Hospital · GBUniversity Hospitals of Leicester NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoorly differentiated thyroid carcinoma (PDTC) is a distinct entity with intermediate prognosis between indolent follicular thyroid cancers and anaplastic carcinoma. The management guidelines are not standardized for these cancers due its low prevalence and limited available literature. Therefore, we did this systematic review with emphasis on current evidence on diagnosis, imaging, molecular markers, and management of these carcinomas. MATERIALS AND

methodsWe searched four databases, PubMed, Medline, EMBASE, and Emcare to identify studies published till October 2023. All studies reporting diagnostic tests, imaging, molecular marker expression and management of PDTC were included in the review. The meta-analysis was conducted on expression of molecular markers in these cancers following recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Random-effects meta-analysis was used to calculate pooled estimated prevalence with 95% confidence intervals. Based on the inclusion criteria, 62 articles were selected to be incorporated for the review. Differences in pathological diagnostic criteria of PDTC was noted in literature which was addressed in WHO 2022 diagnostic terminologies with expansion of the definition. Surgical management is uniformly recommended for early stage PDTC. However, literature is divided and anecdotal for recommendations on radioactive iodine (RAI), extent of neck dissection and adjuvant treatment in PDTC. Evidence for Next Generation Sequencing (NGS), novel theragnostic approaches, immunotherapy targets are evolving. Based on the subset analysis for expression of molecular markers, we found the most common markers expressed were TERT (41%), BRAF (28%) and P 53 (25%).

conclusionPoorly differentiated thyroid carcinomas have a high case fatality rate (up to 31%). Eighty-five % of the patients who succumb to the disease have distant metastasis. Even though under-represented in literature, evidence-based management of these aggressive tumors can help personalize the treatment for optimal outcomes.

Indexed as

Clinical Decision-MakingThyroid NeoplasmsHumansPoorly differentiatedThyroid carcinomaTurin criteria

Identifiers

PMID38504051
OpenAlexW4392938802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.